华领医药-B（02552.HK）今日盘中大涨5.88%，截至发稿报3.92港元，成交额4088.42万港元。该股价上涨主要受到公司最新发布的中期业绩报告的积极影响。
根据华领医药公布的中期业绩，公司在2025年上半年首次实现盈利，标志着其商业化转型取得显著成效。报告期内，公司核心产品华堂宁销量达176.4万盒，同比增长108%，净销售额达2.174亿元，同比增长112%。值得注意的是，公司与拜耳终止独家推广服务协议后，确认了12.435亿元的一次性递延收入，从而推动上半年实现盈利11.839亿元。
华领医药的盈利能力也有显著提升。公司毛利率升至54.2%，较去年同期增长7.7个百分点，这主要得益于生产规模扩大和运营效率的提升。自2025年1月全面接管华堂宁商业化运营后，公司凭借自主销售团队实现了显著增长。同时，随着医保覆盖范围的持续扩大，二级和三级医院的处方量大幅增加，进一步推动了销售增长。此外，华领医药正积极拓展海外业务，加速全球化布局，并持续加大研发投入，为未来发展奠定基础。这些积极因素共同推动了投资者对公司前景的信心，带动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.